Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -17.75
- Piotroski Score 2.00
- Grade Buy
- Symbol (BTAI)
- Company BioXcel Therapeutics, Inc.
- Price $0.58
- Changes Percentage (5.47%)
- Change $0.03
- Day Low $0.55
- Day High $0.59
- Year High $5.62
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/12/2024
- Fiscal Year End N/A
- Average Stock Price Target $10.00
- High Stock Price Target $25.00
- Low Stock Price Target $1.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$5.18
- Trailing P/E Ratio -0.27
- Forward P/E Ratio -0.27
- P/E Growth -0.27
- Net Income $-179,053,000
Income Statement
Quarterly
Annual
Latest News of BTAI
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Amphix Bio obtains FDA breakthrough device status for bone regeneration product
Amphix Bio's bone regeneration product receives FDA breakthrough device status for treating degenerative disc disease through TLIF procedures. The innovative implant stimulates bone growth without don...
By Yahoo! Finance | 1 day ago -
Lana Del Rey obtains marriage license with Louisiana alligator tour guide Jeremy Dufrene
Singer Lana Del Rey and boyfriend Jeremy Dufrene, an airboat captain, obtained a marriage license in September. They have known each other since 2019 and were recently seen at events together. Dufrene...
By USA Today | 1 week ago -
Lana Del Rey Obtains Obtains Marriage License to Wed Alligator Tour Guide Jeremy Dufrene
Lana Del Rey and boyfriend Jeremy Dufrene are taking their relationship to the next level by obtaining a marriage license. The couple, known for several years, plans to marry within 30 days of the lic...
By PEOPLE.com | 1 week ago
